Helsinki spinout Aiforia has raised an initial $15.4m in series B funding, bringing it halfway to the round’s target.
Aiforia, a Finland-based intelligent pathology technology spinout of University of Helsinki, has picked up €12.6m ($15.4m) in a first series B tranche led by cancer diagnostics technology provider Epredia’s UK division.
The tranche featured Aktia Nordic Micro Cap and unnamed existing investors. The round’s target size is $30.8m.
Founded in 2013 as Fimmic, Aiforia is working on a cloud-based artificial intelligence-equipped software that enables preclinical and clinical image analysis in pathology.
The series B funding has been allocated to attracting more customers internationally and to develop and release a platform dedicated to the diagnosis of cancers.
Aiforia previously obtained $1.7m from investors including Tekes and private investors Marten Mickos and Jukka Tapaninen in October 2015. It subsequently added $5.9m in series A funding from Ascend Capital Partners, Acme Investments and STO-Rahoitus in December 2017.
